Image By: George Tidmarsh, M.D., Ph.D., Director, Center for Drug Evaluation and Research Clinical trial transparency is fundamental to maintaining public trust in medical research and […]

Voluntary Reporting For use by Health Professionals, Consumers, and Patients Reporting can be done through our online reporting portal or by downloading, completing and then submitting […]

Speech by Sara Brenner, M.D., M.P.H. Principal Deputy Commissioner – Office of the Commissioner Good morning, and thank you for being here. At FDA, our work […]

The Prescription Drug User Fee Act of 1992 (PDUFA), Biosimilar User Fee Act of 2012 (BsUFA), and Generic Drug User Fee Amendments of 2012 (GDUFA) authorize […]

On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, […]

Reference #: FEI 1025483 Product: Drugs Recipient: Recipient Name Mr. Adalberto R. Cabrera Recipient Title Chief Operating Officer Tarmac Products, Inc. 16311 NW 52nd AVEMiami Gardens, […]

Delivery Method: VIA Electronic Mail Product: Drugs Recipient: Recipient Name Adalberto Cabrera Recipient Title Chief Operating Officer Tarmac Products, Inc. 16311 NW 52nd AvenueMiami Gardens, FL […]

About OTC Monograph Reform On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (Public Law No. 116-136, 134 Stat. 281, 457) […]

OTC MONOGRAPHS @ FDA A resource for the public to view OTC Monographs and their Administrative Orders (Proposed, Final, and Interim Final). OTC Monographs@FDA also facilitates […]